Search Results

Displaying Results 3801-3825 of 4087 "'VS'"

Oct 27, 2025, 06:27 ET Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species

provide leading-edge protection for dogs against a complex and evolving parasitic landscape." Lotilaner vs. Lyme Disease The active ingredient lotilaner in both Credelio Quattro and Credelio has been found highly effective for

More news about: Elanco Animal Health


Oct 26, 2025, 20:00 ET Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3

semaglutide on the primary endpoint—the proportion of participants achieving HbA1c < 7.0% and ≥10% body weight reduction from baseline at week 32 (48.0 vs. 21.0%, p<0.0001). In addition, at week 32, the mean change in HbA1c from baseline was −2.03% in the mazdutide group and −1.84% in semaglutide group,

More news about: Innovent Biologics


Oct 26, 2025, 17:24 ET Three-year SPYRAL HTN-ON MED results show sustained, 18 mmHg office-based blood pressure reductions

24-hour ABPM: −14.0 mmHg in the RDN group vs. −9.3 mmHg in the sham group (treatment difference: −4.7 mmHg; p=0.0028) OSBP: −18.5 mmHg in the RDN group vs. −11.7 mmHg in the sham group (treatment difference: −7.4 mmHg; p=0.0002)

More news about: Medtronic plc


Oct 26, 2025, 15:00 ET Cordis Unveiled Breakthrough Results from SELUTION DeNovo and SELUTION4ISR Randomized Trials at TCT 2025, Transforming Coronary Artery Disease (CAD) Treatment Beyond Stenting

demonstrated non-inferior performance against ISR standard-of-care treatment. Target lesion failure (TLF) at 12-months was 15.2% with SELUTION SLR™ DEB vs. 13.5% in standard of care control which was comprised of 80% DES. These results will be leveraged to support a submission to FDA for coronary ISR indication

More news about: Cordis


Oct 24, 2025, 18:32 ET Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

increase from baseline) was observed in more than twice as many patients in the high dose nipocalimab group (15 mg/kg) compared to the placebo group (33% vs. 16%, respectively) at Week 24.1 "The DAHLIAS Phase 2 study represents an important step forward in the understanding

More news about: Johnson & Johnson


Oct 24, 2025, 13:24 ET CA Oversight Report Shows Decade of Gasoline Price Gouging, says Consumer Watchdog

report also found refining margins at branded gasoline stations were much greater than at unbranded stations over the last decade – 75 cents per gallon vs 41 cents per gallon. This shows vertically integrated refiners, such as Chevron and Marathon, have used their market power to jack up rates at branded

More news about: Consumer Watchdog


Oct 24, 2025, 10:33 ET KuCoin Brings Fresh Brand, Trust-Driven Innovation, and Mining Vision to Dubai's Blockchain Life 2025

sustainability, and user empowerment. KuCoin's thought leadership continues with Managing Director Alicia Kao joining the panel "DEX vs. CEX: Evolution of Exchange and New Competition" on October 28, alongside other top industry leaders, to explore the future of trading and exchange

More news about: KuCoin


Oct 24, 2025, 10:15 ET KuCoin Brings Fresh Brand, Trust-Driven Innovation, and Mining Vision to Dubai's Blockchain Life 2025

sustainability, and user empowerment. KuCoin's thought leadership continues with Managing Director Alicia Kao joining the panel "DEX vs. CEX: Evolution of Exchange and New Competition" on October 28, alongside other top industry leaders, to explore the future of trading and exchange

More news about: KuCoin


Oct 24, 2025, 08:00 ET Consumer Edge Announces Beta Launch of AI-Powered Chat to Transform How Companies Uncover More Insights, Faster

Any Question, Instant Answers: Come with any question using transaction level data and receive results in minutes vs. weeks. Natural-Language Querying: Ask questions in plain English—no SQL or code required.

More news about: Consumer Edge


Oct 24, 2025, 06:24 ET Supermicro breidt haar portfolio oplossingen voor Cloud Service Providers uit met de nieuwe 6U 20-node MicroBlade® , aangedreven door AMD's processoren van de EPYC™ 4005-serie

volgende generatie, van cloud tot edge, aan te bieden aan onze wereldwijde klanten. Onze producten worden in eigen huis ontworpen en geproduceerd (in de VS, Taiwan en Nederland). Hierbij maken we gebruik van wereldwijde faciliteiten voor schaal en efficiëntie, geoptimaliseerd om de TCO te verlagen en de impact

More news about: Super Micro Computer, Inc.


Oct 23, 2025, 18:13 ET Bridgestone Launches RACING BATTLAX V03 Slick Motorcycle Tire

2 Comparison based on internal testing of the Bridgestone BATTLAX V03 tire vs. the Bridgestone BATTLAX V02 tire on BMW M 1000 RR superbike in Oschersleben, Germany. Results may vary depending upon proper tire and bike maintenance,

More news about: Bridgestone Americas, Inc.


Oct 23, 2025, 17:01 ET Oakworth Capital Inc. Reports 22% Increase in Diluted EPS

9/30/2025 vs. 06/30/2025

More news about: Oakworth Capital Inc.


Oct 23, 2025, 16:15 ET Associated Banc-Corp Reports Third Quarter 2025 Net Income Available to Common Equity of $122 Million, or $0.73 per Common Share

interest income of $305 million (+2% vs. 2Q 2025; +16% vs. 3Q 2024) Total period end loans of $31.0 billion (+1% vs. 2Q 2025; +3% vs. 3Q 2024) Total period end deposits of $34.9 billion (+2% vs. 2Q 2025; +4% vs. 3Q 2024) Total

More news about: Associated Banc-Corp


Oct 23, 2025, 16:05 ET Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

pre-specified subgroups, including patients with IDH-wild-type and IDH-mutant tumors. Other key secondary endpoints, including disease control rate (54% vs 27.5%), and delay to deterioration in pain and physical function, further supported the clinical benefit observed with ozekibart.

More news about: Inhibrx Biosciences, Inc.


Oct 23, 2025, 16:01 ET Miami-Dade Real Estate Registers Best Sales Month of the Year

all-cash sales in the first half of 2025 via Realtor.com. 43% of all real estate deals in Miami are all-cash. A high all-cash market is strengthened vs. recessions and more immune to rising mortgage rates. Miami-Fort Lauderdale-West Palm Beach ranked No. 3 in the U.S. in Skilled

More news about: MIAMI Association of REALTORS®


Oct 23, 2025, 15:38 ET LG JOINS 'SDVERSE' TO ACCELERATE SOFTWARE-DEFINED MOBILITY INNOVATION

innovation with LG AphaWare." About LG Electronics Vehicle Solution CompanyThe LG Vehicle Solution (VS) Company is bringing LG's unique human-centered innovations to the automotive industry. As a trusted and innovative partner, the company provides intelligent

More news about: LG Electronics USA


Oct 23, 2025, 11:26 ET Community Heritage Financial, Inc. Announces Third Quarter 2025 Financial Results

pressure from mortgage banking activities and bank-owned life insurance performance. Third Quarter 2025 vs. Third Quarter 2024 – Noninterest income decreased $92 thousand. Mortgage banking revenue decreased $160 thousand reflecting market challenges mentioned

More news about: Community Heritage Financial, Inc.


Oct 23, 2025, 09:04 ET New EY survey reveals majority of workers are enthusiastic about Agentic AI, but leadership gaps in communication and lack of training threaten impact

compared to those without clear communication. Employees at these organizations are also more likely to use agentic AI (66% vs. 39%) and are eager to embrace agentic AI in their role (87% vs. 69%) compared to those at organizations without clear communication.

More news about: EY


Oct 23, 2025, 08:30 ET ESQUIRE FINANCIAL HOLDINGS, INC. REPORTS THIRD QUARTER 2025 RESULTS

Third Quarter 2025 vs. 2024 Net income for the quarter ended September 30, 2025 was $14.1 million, or $1.62 per diluted share, compared

More news about: Esquire Financial Holdings, Inc.


Oct 23, 2025, 08:00 ET Joint Genome Institute Demonstrates Feasibility of Alveo Technologies' Portable Molecular Testing Platform for Wastewater Pathogen Surveillance

data that helps guide response and protect public health. We hope our platform will be utilized as 'a trip-wire-like tool to monitor-detect-mitigate vs. detect-respond.' Deploying our technology in this manner can help keep pathogen horses in the barn before they wreak havoc on populations."

More news about: Alveo Technologies, Inc.


Oct 23, 2025, 06:30 ET G Mining Ventures Announces Formal Construction Decision for the Oko West Gold Project and Provides Project Development Update

costs: Increased due to additional construction equipment purchases Pre-production revenue: 30,000 ounces ("oz") at $3,200/oz vs $2,500/oz in FSContingency (incl. pre-production revenue): 8.8%

More news about: G Mining Ventures Corp


Oct 23, 2025, 06:00 ET Dow reports third quarter 2025 results

vs. SQLY

More news about: The Dow Chemical Company


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.